Agomab anticipates $182M IPO as it builds fibrosis pipeline

Belgium's Agomab Therapeutics seeks up to $828.5 million valuation in US IPO

Agomab Therapeutics is targeting a valuation of up to $828.5 million in its ​initial public offering in the United States, the Belgium-based company ‌said on Thursday.

Agomab anticipates $182M IPO as it builds fibrosis pipeline

Belgian fibrosis biotech Agomab Therapeutics plans to collect about $182 million in net proceeds from its proposed Nasdaq IPO. The company anticipates selling 12.5 million shares at $15 to $17 each under the ticker symbol ...